References
- Citarella R., Wallace R., Murdock K. C., Angier R., Durr F., Forbes M. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboaldehyde bis (4,5-dihy-dro-lH-imidazol-2-yl) hydrazone dihydrochloride, against experimental tumors in mice. Cancer Research 1982; 42: 440–444
- Alberts D., Mackel C., Pocelinko R., Salmon S. Phase I clinical investigation of 9,10-anthracenedicarbox-aldehyde bis (4,5-dihydro-lH-imidazol-2-yl) hydrazone dihydrochloride with correlative in vitro human tumor clonogenic assay. Cancer Research 1982; 42: 1170–1175
- Bowden G., Garcia D., Peng Y., Alberts D. Molecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxaldehyde bis (4,5-dihydro-lH-imidazol-2-yl) hydrazone dihydrochloride (Cl 216,942). Cancer Research 1982; 42: 2660–2665
- Robbie M., Wilkins R. J. Identification of the specific sites of interaction between intercalating drugs and DNA. Chem. Biol. Interactions 1984; 49: 189–207
- Feigon J., Denny W., Leupin W., Kearns D. Interactions of antitumor drugs with natural DNA: H NMR study of binding mode and kinetics. J. Med. Chem. 1984; 27: 450–465
- Marty M., Ferme C., Gisselbrecht C., Guy H., Clark M. J., Bancillon A., Boiron M. Phase I study of bisantrene in acute nonlymphoblastic leukemia. Cancer Treatment Reports 1985; 69: 703–705
- Marty M., Isnard F., Gourmel G., Lefebvre P., Gisselbrecht C., Espie M., Boiron M. Bisantrene: an anthracene derivative active in ANLL: phase II study. In: F. Mandelli. (ed) 4th International Symposium on Therapy of Acute Leukemias, Roma, 1987; 447, Abs n. 598
- WORLD HEALTH ORGANIZATION. WHO handbook for reporting results of cancer treatment. WHO publication 38, Geneva 1987
- Tosi P., Visani G., Colombini R., Verlicchi F., Benfenati D., Cenacchi A., Russo D., Zufla E., Papadopulu P., Tura S. Phase II study on bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL). Haematologica 1989; 74: 555–558